Nektar Therapeutics

NKTR
Delayed Nasdaq - 05/17 10:00:00 pm
32.02USD
+2.17%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Biotechnology & Medical Research - NEC
Sales per Businesses
20162017
USD
(in Million)
%USD
(in Million)
%
License, Collaboration and Other60.3836.5%210.9768.6%
Product55.3533.5%32.6910.6%
Non-cash Royalty Revenue Related to Sale of Future Royalties30.1618.2%30.539.9%
Royalty19.5411.8%33.5310.9%
Sales per Regions
20162017
USD
(in Million)
%USD
(in Million)
%
Europe126.2976.3%116.9038%
United States39.1523.7%190.8162%
All Other Countries----
Germany and Netherlands----
India----
Managers
Name Title
Howard W. Robin President, Chief Executive Officer & Director
Robert B. Chess Chairman
John Nicholson Chief Operating Officer & Senior Vice President
Gilbert M. Labrucherie Chief Financial Officer & Senior Vice President
Stephen K. Doberstein Chief Research & Development Officer
Mary Tagliaferri Chief Medical Officer & SVP-Clinical Development
Jonathan Zalevsky Chief Scientific Officer & Senior VP-Research
Roy A. Whitfield Independent Director
Lutz Lingnau Independent Director
R. Scott Greer Independent Director
Shareholders
Name Equities %
Fidelity Management & Research Co. 23,088,888 13.3%
PRIMECAP Management Co. 20,154,922 11.6%
The Vanguard Group, Inc. 18,672,131 10.8%
OppenheimerFunds, Inc. 17,302,925 10.00%
BlackRock Fund Advisors 10,084,439 5.83%
Wellington Management Co. LLP 7,703,118 4.45%
SSgA Funds Management, Inc. 6,612,531 3.82%
Henderson Global Investors Ltd. 2,526,961 1.46%
Norges Bank Investment Management 2,424,788 1.40%
First Trust Advisors LP 2,309,172 1.33%
Company contact information
455 Mission Bay Boulevard South
CA 94158 San Francisco, California
États-Unis (les)

Phone : +1 415 482 5300
Fax : +1 415 339 5300
Internet : https://www.nektar.com/
Markets and indexes
- Nasdaq Stock Market
- Nasdaq Global Select Market
- SP 500 /
Stock Exchange Codes
- Reuters Code :  NKTR.O
Sector Biotechnology & Medical Research - NEC
1st jan.Capi. (M$)
NEKTAR THERAPEUTICS-2.59%5 581
IQVIA HOLDINGS INC15.06%26 365
LONZA GROUP24.54%23 366
CELLTRION, INC.--.--%21 024
INCYTE CORPORATION21.40%16 555
EXACT SCIENCES CORPORATION52.44%12 422
SEATTLE GENETICS, INC.17.23%10 715
IONIS PHARMACEUTICALS INC24.68%9 458
SAGE THERAPEUTICS INC75.35%8 591
QIAGEN7.61%8 557
BIO-TECHNE CORP36.44%7 478
ICON PLC6.39%7 419
ALNYLAM PHARMACEUTICALS, INC.-7.37%7 195
CHARLES RIVER LABORATORIES INTL. INC14.05%6 293
GALAPAGOS25.99%6 185
GALAPAGOS NV (ADR)23.01%6 184
PRA HEALTH SCIENCES INC-5.31%5 718
HANGZHOU TIGERMED CONSULTING CO LTD--.--%5 045
SYNEOS HEALTH INC5.29%4 299
BLUEPRINT MEDICINES CORP50.81%3 972
UNITED THERAPEUTICS CORPORATION-16.76%3 971